The non‐haematopoietic biological effects of erythropoietinMurat O. Arcasoy|British Journal of Haematology|2008Cited by 353
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-ISrđan Verstovšek, H. Kantarjian, Ruben A. Mesa et al.|Haematologica|2013Cited by 162
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Vikas Gupta, Roni Tamari et al.|Biology of Blood and Marrow Transplantation|2015Cited by 142
Erythropoietin Blockade Inhibits the Induction of Tumor Angiogenesis and ProgressionMatthew E. Hardee, Murat O. Arcasoy|PLoS ONE|2007Cited by 99